HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

PD 156707

a non-peptide endothelin A receptor-selective antagonist; structure given in first source

Also Known As:

CI 1020; PD-156707

Networked: 5 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Dioxoles
    - PD 156707: 5

Experts

1.	Coceani, Flavio: 1 article (08/2002)
2.	Coe, Yashu: 1 article (08/2002)
3.	Haleen, Stephen J: 1 article (08/2002)
4.	Liu, You-An: 1 article (08/2002)
5.	Welch, Kathleen M: 1 article (08/2002)
6.	Bekker, J M: 1 article (02/2001)
7.	Black, S M: 1 article (02/2001)
8.	Fineman, J R: 1 article (02/2001)
9.	Gerrets, R: 1 article (02/2001)
10.	Hendricks-Munoz, K: 1 article (02/2001)

Related Diseases

1.	Infarction (Infarctions) 07/01/1996 - "PD 156707 had no effect on infarct size (61.1 +/- 5.6% of the region at risk in the PD 156707 treatment group vs. 70.1 +/- 3.9% in the control group). " 07/01/1996 - "The purpose of this study was to determine if selective blockade of ET(A) receptors by PD 156707 reduces infarct size caused by coronary artery occlusion and reperfusion in pentobarbital-anesthetized micropigs. " 07/01/1996 - "Endothelin A receptor antagonism by PD 156707 does not reduce infarct size after coronary artery occlusion/reperfusion in pigs." 03/01/1996 - "PD 156707 failed to block the protection from ischemic preconditioning (12.6 +/- 2.3% infarction) revealing that endothelin is not an important physiological mediator of ischemic preconditioning. "
2.	Myocardial Infarction 07/01/1996 - "In myocardial infarction studies, micropigs received either saline vehicle (n = 7) or PD 156707 (n = 8) at a loading dose of 10 mg/kg/1 hr, followed by a maintenance dose of 7 mg/kg/hr. Coinciding with the start of the maintenance dose, the left anterior descending coronary artery was occluded for 1 hr followed by 3 hr of reperfusion. "
3.	Pulmonary Hypertension 02/01/2001 - "The objectives of this study were to determine the effects of inhaled NO on endogenous ET-1 production in vivo in the intact lamb and to determine the potential role of ET-1 in the rebound pulmonary hypertension associated with the withdrawal of inhaled NO. Seven 1-mo-old vehicle-treated control lambs and six PD-156707 (an ET(A) receptor antagonist)-treated lambs were mechanically ventilated. "
4.	Ischemia 01/01/1999 - "Three nephrectomized groups that did not undergo ischemia but that received infusions of saline (N = 6), PD 156707 (N = 6), and SB 209670 (N = 6), respectively, were also studied. " 01/01/1999 - "Twenty-four hours after renal ischemia, one of two ETR antagonists, PD 156707 (N = 7) or SB 209670 (N = 8), was administered. "
5.	Hypoxia (Hypoxemia) 08/01/2002 - "Consistent with findings in vivo, when using isolated pulmonary resistance arteries from term fetal lamb, PD 156707 curtailed the hypoxia- but not the ONO-11113-induced constriction. " 08/01/2002 - "We conclude that PD 156707 and PD 180988 are selective inhibitors of pulmonary vasoconstriction resulting from hypoxia. "

Related Drugs and Biologics

1.	Pentobarbital (Nembutal)
2.	Endothelin A Receptor
3.	Endothelins (Endothelin)
4.	PD 180988
5.	(1S,2R,3S)- 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)- 4- methoxyphenyl)- 2,3- dihydro- 5- propoxy- 1H-Indene-2-carboxylic acid